Tyrosine Kinase Inhibitors in the Treatment of Eosinophilic Neoplasms and Systemic Mastocytosis.
Sign Up to like & getrecommendations! Published in 2017 at "Hematology/oncology clinics of North America"
DOI: 10.1016/j.hoc.2017.04.009
Abstract: The World Health Organization's semimolecular classification of eosinophilias emphasizes neoplasms driven by fusion tyrosine kinases. More than 80% of patients with systemic mastocytosis carry the KIT D816V mutation, the primary driver of disease pathogenesis. Genetic… read more here.
Keywords: kinase inhibitors; eosinophilic neoplasms; systemic mastocytosis; tyrosine kinase ... See more keywords